ABUS Arbutus Biopharma Corp
Price (delayed)
$3.31
Market cap
$627.22M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.43
Enterprise value
$596.82M
Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple
Highlights
The debt has declined by 24% year-on-year and by 9% since the previous quarter
ABUS's quick ratio is up by 12% YoY and by 8% QoQ
Arbutus Biopharma's revenue has shrunk by 70% YoY and by 33% QoQ
Arbutus Biopharma's gross profit has shrunk by 70% YoY and by 33% QoQ
Key stats
What are the main financial stats of ABUS
Market
Valuations
Earnings
Shares outstanding
189.49M
Market cap
$627.22M
Enterprise value
$596.82M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.85
Price to sales (P/S)
92.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
88.52
Revenue
$6.74M
Gross profit
$6.74M
Operating income
-$82.17M
Net income
-$76.7M
EBIT
-$76.55M
EBITDA
-$75.14M
Free cash flow
-$71.92M
Per share
Balance sheet
Liquidity
EPS
-$0.43
EPS diluted
-$0.43
Free cash flow per share
-$0.38
Book value per share
$0.57
Revenue per share
$0.04
TBVPS
$0.74
Total assets
$140.44M
Total liabilities
$33.55M
Debt
$1.45M
Equity
$106.89M
Working capital
$113.85M
Debt to equity
0.01
Current ratio
7.02
Quick ratio
6.84
Net debt/EBITDA
0.4
Margins
Efficiency
Dividend
EBITDA margin
-1,114.6%
Gross margin
100%
Net margin
-1,137.6%
Operating margin
-1,218.8%
Return on assets
-51.5%
Return on equity
-68.2%
Return on invested capital
-86.7%
Return on capital employed
-63%
Return on sales
-1,135.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ABUS stock price
How has the Arbutus Biopharma stock price performed over time
Intraday
0%
1 week
-0.3%
1 month
-3.78%
1 year
29.8%
YTD
1.22%
QTD
1.22%
Financial performance
How have Arbutus Biopharma's revenue and profit performed over time
Revenue
$6.74M
Gross profit
$6.74M
Operating income
-$82.17M
Net income
-$76.7M
Gross margin
100%
Net margin
-1,137.6%
Arbutus Biopharma's revenue has shrunk by 70% YoY and by 33% QoQ
Arbutus Biopharma's gross profit has shrunk by 70% YoY and by 33% QoQ
ABUS's operating margin is down by 49% since the previous quarter
The net margin has declined by 48% since the previous quarter
Growth
What is Arbutus Biopharma's growth rate over time
Valuation
What is Arbutus Biopharma stock price valuation
P/E
N/A
P/B
5.85
P/S
92.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
88.52
The company's EPS rose by 7% YoY and by 4.4% QoQ
ABUS's price to book (P/B) is 89% higher than its 5-year quarterly average of 3.1 and 19% higher than its last 4 quarters average of 4.9
Arbutus Biopharma's equity has decreased by 13% QoQ and by 10% YoY
Arbutus Biopharma's revenue has shrunk by 70% YoY and by 33% QoQ
The price to sales (P/S) is 66% higher than the last 4 quarters average of 55.9
Efficiency
How efficient is Arbutus Biopharma business performance
The company's return on sales fell by 49% QoQ
The ROIC has declined by 48% year-on-year and by 8% since the previous quarter
Arbutus Biopharma's return on assets has decreased by 23% YoY and by 2.4% QoQ
The ROE is down by 21% year-on-year and by 2.2% since the previous quarter
Dividends
What is ABUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ABUS.
Financial health
How did Arbutus Biopharma financials performed over time
ABUS's total liabilities is down by 15% year-on-year and by 11% since the previous quarter
The company's total assets fell by 12% QoQ and by 11% YoY
The debt is 99% smaller than the equity
ABUS's debt to equity has dropped by 50% year-on-year
The debt has declined by 24% year-on-year and by 9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.